<DOC>
	<DOCNO>NCT01984528</DOCNO>
	<brief_summary>The objetive study determine minimum amount Alternaria alternata allergen extract produce positive skin reaction .</brief_summary>
	<brief_title>To Determine Minimum Amount Alternaria Alternata Allergen Extract Producing Positive Skin Reaction .</brief_title>
	<detailed_description>This open , unblinded non-randomized biological assay . The primary objective ass concentration alternaria alternata allergen extract elicit wheal size equivalent 10 mg/ml histamine dyhidrochloride solution .</detailed_description>
	<criteria>Positive clinical history inhalatory allergy Alternaria alternata . Subject provide write informed consent , appropriately sign date subject . Subject male female race ethnic group . Age &gt; =18 year &lt; = 60 year study inclusion day . Positive skin prick test standardize commercially available preparation Alternaria alternata allergen extract . The skin prick test consider positive test result wheal major diameter least 3 mm wheal area ≥ 7 mm2 . Positive skin prick test result valid perform within one year prior inclusion subject study . A positive test specific IgE alternaria alternata ( CAPRAST major equal 2 ) . IgE result valid perform within one year prior inclusion subject study . The mean wheal diameter obtain histamine dihydrochloride ( 10 mg / ml ) forearm ≥ 3 mm . Immunotherapy past 5 year allergen preparation know interfere allergen test ( example : fungal extract ) Use drug may interfere skin reaction ( e.g. , antihistamine ) . Treatment follow medication : oral tricyclic tetracyclic antidepressant , betablockers , corticosteroid ( major 10 mg/daily prednisone equivalent ) . Women pregnant breastfeeding period woman positive pregnancy test Visit 1 2 . Dermographism affect skin area test site either study visit . Atopic dermatitis affect skin area test site either study visit . Urticaria affect skin area test site either study visit . Diseases immune system relevant clinically , autoimmune immunodeficiency . Serious disease control may increase risk safety subject involve study , include , limited following : heart failure , uncontrolled severe respiratory disease , endocrine disease , clinically relevant kidney liver diseases hematological disease . Participation clinical trial within 30 day prior inclusion subject clinical trial . Patients diseases condition limit use adrenaline ( heart disease , severe hypertension ) . Severe psychiatric , psychological neurological disorder . Abuse alcohol , drug medicine previous year . Subjects receive antiIgE ( Omalizumab ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Skin prick test</keyword>
	<keyword>Standardization</keyword>
	<keyword>Alternaria alternata</keyword>
</DOC>